Prospective Clinical Assessment Study in Children With Hypochondroplasia

NCT ID: NCT06410976

Last Updated: 2025-10-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-06-05

Study Completion Date

2026-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a long-term, multicenter, non-interventional study of children ages 2.5 to \<17 years with hypochondroplasia (HCH).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective is to evaluate growth, HCH-related medical complications, health-related quality of life, functional abilities and cognitive functions of study participants. Data collected will contribute to the characterization of the natural history of children with HCH. No study medication will be administered.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypochondroplasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Signed informed consent.

Aged 2.5 to \<17 years at study entry.

Diagnosis of HCH documented clinically by the presence of disproportionate short stature and confirmed with a molecular test.

Participants are ambulatory and able to stand without assistance.

Study participants and parent(s), guardian(s), or caregiver(s) are willing and able to comply with study visits and study procedures.

Exclusion Criteria

Have ACH or short stature condition other than HCH.

In females, having had their menarche. Annualized height growth velocity ≤1.5 cm/year over a period ≥6 months prior to screening.

Having a clinically significant disease or condition that in view of the investigator or Sponsor will interfere with the evaluation of growth, with study participation or not be in the best interest of the participant.

Clinically significant abnormality in any laboratory test result at screening

Current evidence of corneal or retinal disorders.

Have used any other investigational or approved product or medical device for the treatment of HCH or short stature for ≥ 30 days or with the last dose \<6 months before screening.

Have had regular long-term treatment (\>1 month) with oral corticosteroids (low-dose ongoing inhaled steroid for asthma is acceptable).

Previous limb-lengthening surgery or guided growth surgery with plates still in place or removed within the 6 months prior to screening.

Having had a fracture of the long bones or spine within 12 months of screening.

History and/or current evidence of extensive ectopic tissue calcification.

History of malignancy.

Concurrent circumstance, disease, or condition that, in the view of the investigator and/or sponsor, would interfere with study participation, and/or would place the participant at high risk for poor compliance with study activities or for not completing the study.

Current participation in any other ongoing clinical study with another sponsor.
Minimum Eligible Age

30 Months

Maximum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

QED Therapeutics, Inc., a Bridgebio company

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UCSF Benioff Children's Hospital

Oakland, California, United States

Site Status RECRUITING

Childrens Hospital Colorado

Aurora, Colorado, United States

Site Status RECRUITING

Children's National Hospital

Washington D.C., District of Columbia, United States

Site Status RECRUITING

Johns Hopkins School of Medicine

Baltimore, Maryland, United States

Site Status RECRUITING

University of Missouri

Columbia, Missouri, United States

Site Status RECRUITING

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

Site Status RECRUITING

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Site Status RECRUITING

University of Wisconsin Madison - Waisman Center Bone Dysplasia Clinic

Madison, Wisconsin, United States

Site Status RECRUITING

Murdoch Children's Research Institute

Parkville, Victoria, Australia

Site Status RECRUITING

London Health Sciences Centre - Children's Hospital of Western Ontario

London, Ontario, Canada

Site Status RECRUITING

Children's Hospital of Eastern Ontario Research Institute

Ottawa, Ontario, Canada

Site Status RECRUITING

Université de Montréal - Centre Hospitalier Universitaire Sainte-Justine

Montreal, Quebec, Canada

Site Status RECRUITING

Hôpital Femme Mère Enfant HCL

Bron, , France

Site Status RECRUITING

Hôpital Necker-Enfants Malades

Paris, , France

Site Status RECRUITING

Centre Hospitalier Universitaire (CHU) de Toulouse - Hôpital des Enfants

Toulouse, , France

Site Status RECRUITING

Haukeland University Hospital

Bergen, , Norway

Site Status RECRUITING

Paediatric Clinical Research Unit at Oslo University Hospital

Oslo, , Norway

Site Status RECRUITING

Hospital Pediátrico de Coimbra

Coimbra, , Portugal

Site Status RECRUITING

KK Women's and Children's Hospital

Singapore, , Singapore

Site Status RECRUITING

Hospital Vithas San Jose

Vitoria-Gasteiz, , Spain

Site Status RECRUITING

Astrid Lindgren Children's Hospital

Solna, , Sweden

Site Status RECRUITING

The Portland Hospital for Women and Children

London, England, United Kingdom

Site Status RECRUITING

Manchester University

Manchester, England, United Kingdom

Site Status RECRUITING

Sheffield Children's NHS Foundation Trust

Sheffield, England, United Kingdom

Site Status RECRUITING

Glasgow Clinical Research Facility, Queen Elizabeth University Hospital

Glasgow, Scotland, United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Canada France Norway Portugal Singapore Spain Sweden United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

QED Therapeutics, Inc

Role: CONTACT

1-877-280-5655

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

QBGJ398-004

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.